Previous 10 | Next 10 |
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.78% on the day to $57.6. Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and...
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is the focus of IBN's latest stock spotlight. The company's shares have moved 12.93% on the day to $55.95. Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological an...
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments PR Newswire Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targetin...
2024-02-18 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-16 12:38:39 ET More on Biohaven Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade) UBS starts Biohaven at buy, cites diverse pipeline Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohaven Financial information ...
2024-02-07 15:03:42 ET More on Biohaven Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade) Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohaven Financial information for Biohaven Read the full article on Seeking Alp...
2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-02-01 07:22:58 ET Summary Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars ...
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology PR Newswire Five p...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments PR Newswire Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024 , which excludes the net proceeds of approximatel...